joining XXXX this Volition’s Scott, at taking you quarter for in conference for for you, I you time to second interest everyone key would thank again Thank us. all and thank call. earnings like Volition
past additional the to areas aggregate sheet this of exercised great in all numerous will cash any months. the product significant the I XX of joins fronts, I’m our $X made from me within Italy, and we our to Namur considerably We price our that on complete of Vanston, many target approximately the David today. Financial last we within year. at square additional the been purpose-built progress that that of plus strengthened team have XX,XXX-plus staff on with believe Belgium possible lab which and We made XX long-term current our funding months, has trials with This be on $XX.X we’re foot progress call million the research many In revenues gives by growing development a per we of us to making could in million and be including than week Scott, along also of financing the position. on puts our achievements position the That if larger launches next kits recent range Officer hand exciting sales news investor. in so delighted to and lever closing and facility $X to like of company. developments. next position, in $XX well the of a in addition cash product a with the we an expert with X non-dilutive our continue our exercised, outstanding great existing opened In have Chief $XX expenditures. heard balance warrants more long which that the cash as exercise of us further equity cash gives which provide aim by would XX, expire June to share some runway to highlight million to with Furthermore, made million $X
demonstrates exciting we we cancer a believe our and and cash the burn preliminary of a minimize it possible very prostate a that trial, from We if are be numerous larger announced taking consideration the data We rate careful to once our are into the keep more will technology. the in the this stable, development our results significant that stage line platform breakthrough opportunity. to validated a extremely Such of further potential trial, are gives for in breath water activities yesterday market a data conducting. us And product.
recently our We impact prestigious endometriosis in DNA the tumor company’s in also cancer announced one also with success. Oxford, areas enrichment our of the completion the sample Progress these on made of that delivery origin the have on University product would of been We in have significant collection the study the England. BonnXX has of of study work. of believe
our Now quarter. second let’s financial the developments during review results and
of during for analytically work year level analytical the of reproducible large focus help is assays smaller will the our past in that of trials our very be Our half from first to mean amount team a step our in on clinical development but not completed needs albeit, incredible of product clinical the the needed trials has process, products a can particularly validated advancing consuming was XXXX development any be time they Throughout terms in that grade This laboratories work clinical our for By our critical, will very success and worldwide. and to an so I it’s ensure the where can product press much ready. and fruit. This run of anywhere and in that key development lab. the in releases. is clinics that bearing be now grade validity future be assays
much from thank and a usable in This very of I’ll efforts. for being is outline team team which of today. would areas, now the dedicated dedicated I our like becoming wide range their critical used However, of is some mountain to work
Our product two-pronged followed the development approach.
be grade First, assays trials can we in publications. and used clinical integrate improvements all our discovery into that
assays. data ago. that improvements XX on nucleosomes at grade prostate For cancer artificial discovery in released exciting we calibrants, the include yesterday These impossible the was something work even significant utilizing initial believe example, months
a assays the a population lot second diseases other discovery also expect trial of We underway these in grade have of the XXX in months. samples a other few second to cancers range update European different of in with trials and and on discovery next
then be and we grade is product any assays components for run in take for grade further The lab final a the with discovery trials. used in and in well life This to growing large very worldwide. are kits work Belgium. them and shelf validation team including research develop lab second in product our to at long assays robustness needed has trialing gone the These all the prong our
first is from Giving the scratch. robust development much work undertaken. time of However, to we proven it have groups field had and work has be fair are assays Nucleosomics who say on to to a has worked consuming of in done massive be this that the the
our with regards to the clinical approach, larger milestones the we’re cancer. previously communicated family product taking has Our believed of correct delayed in the colorectal but trials it achievement
For to undertaken work amounts order a of work product from for assay of completed assays. discovery is XX trials. stage of for magnitude each we future of have these a minimum successful to requires XX and This stage individual need the the each assays we when experiments, developing describe the carried to-date, product
of So that it foundation a is strong view knowledge base extremely building for clinical of as we and an work opportunities. wide what is and of a product range
only product which scale challenges the asset project trials clinical scale the assays, and biggest tumor most nucleosomes white blood only circulating fraction but Our from it analytical work of from to a note or of of our cells. quarter DNA very circulating delayed. that is all circulating tumor does that the last investigating is not or helped origin. one Only coming by a This considerable had of we in a ongoing, provide dead DNA of most call been that work facing exciting enlarged clinical company has large is separate samples circulate samples. enrich cell-free study has DNA and mentioned come intellectual particular, and the last further the the is fact company five are at DNA origin to anticipations Since of itself, nucleosomes nucleosomes cell-free the small study well most on hope has, ability of add from diagnostic the quarters. background, another in why is our updates results recently structure, validation potential quality tumor want purified proceeding with property, been the use to Therefore, origin. to in a in On did test to value samples, the proven, to different valuable the the to advancement DNA nucleosomes way have of the I’ve of company. tumor purify a the be By known large circulating we of
week. a the of $X Now quarter from equivalents, we the million closed million from the private closed XXXX and position June our equity from financial with strong in out $XX.X of in XX, last gross cash excludes a proceeds placement that which second cash we securities ended perspective
research for of close We controls around Yet we to industry, of budget, minister more from all secured have cash despite additional have the and marketing demonstrates employment, agencies to $X.X I’m Regional average digital, $X.X once to-date we economy, This underlying this on from our quarter of Belgium. costs, in of $XXX,XXX Walloon use and like that also and completed non-dilutive non-dilutive funding million latest agencies. that with a and wisely. of many of the cash funding the training would availability carefully which level in continued support an activity keep thank approximately of Jeholet quarterly delighted again and of local Pierre-Yves an of the Volition. in development very reserved burn particular number million. aggregate an We the Mr. tight funding in relatively ongoing to milestones a high take to Government ability total the
including also number of a a facility our the members. video We interviews team released with showcasing
our as helps life If I’d you call I on you’ve our really discussed bring encourage not at have view today. what of website seen much to it it to already, it
our kits, closely a has these clinical work result We an As assisted recombinant assays a with as trial for we clinical something sales have such done done our work greatly the new kits in of last generate of that we Active with research huge Motif Motif, perfects and is critical RUO addition also kits amount on technically possible of This ourselves. as of announced exclusive Active of with distribution agreement in kits. quarter direct background to global this to development only of working manufacturing nucleosomes, became research clinical signing year. aspects work, have range getting license, research, grade us our
the the allow Volition for kits inflammatory of as used patents cancers, and broad in researchers and Active and purposes. for research of The clinical opportunity screening commercialization excellent of including the will circulating happy Volition in the epigenetics applications, beyond research working provide assays kits test. Motif use to reminder, is this a diseases. many additional a infectious based cancer be we we is blood key and maybe other same of are to that epigenetic panels, an cancer across our This very modifications revenue As with but field explore nucleosomes platform a player range an them. will stream hope
our validation products Total kit of Indeed, protected for The Active intellectual believe generate available property patent become will platform. first potential forward, the and and valuable the is moving of kits research now in an has and Nu.Q further been Motif. finalized medicine. additional kit, applications sale will broaden areas sale increasingly We that covering also believe assay Nucleosomics through portfolio asset we biology Volition’s of these
the in just intellectual Our world will and our sent utilize diseases aim our rapidly be The through to will biological and cancer. for many expand collaborate of we our their property in a platform organizations field. to range not areas, as the companies can belief with based the kits. fact and on kits and that health governs platform them is shipping us It researchers allow research around epigenetics many processes other
of for in diseases in with Executive products stated, best field epigenetics Fernandez, research kits nucleosomes a a explore Nucleosomics potential continuously and think different insight breakthrough looking the are these samples. Officer believe technology. new epigenetic of researches is kits throughout clinical comes from across quote that of circulating Motif the Dr. is we will modifications provide These a who the world the I to Chief from Active the way Joseph from who previously innovative
targets is are We to rollout. now the for available sales for future a develop first continued that range kit work important with of broad it to on assays delighted Volition and focused
to of cancer lead trial We expect than studies requirement trials kits. in the this Taiwan detection diagnosis purposes. our Asian addition of with Asian the test the clinical of research are two approximately of for announce we’re sale a to quarter rather and from XX,XXX signing colorectal delighted with subject these for National Nu.Q University, collaboration commencement From perspective, in revenue X,XXX and platform second professor, the already And the By the asymptomatic with a platform patients. and including multi-center subject the trial Chiu. up the way first in the XX,XXX investigator colorectal commercializing are its world-renowned for subjects. Volition’s multi-ethnic screening multi-country, conducted scale would demonstrate large These be include and Nu.Q Han-Mo to regulatory of further and colorectal These cancer part to trial symptomatic will marketing, Asia-Pacific European of study are validate X,XXX reminder, and region Asian cohorts being that existing U.S. cancer globally leaders. and institutions to subject Volition’s key collaborating opinion through plus studies cohorts commitment proprietary principal
XX Bonn, around This the indeed available; heard our become already and assays we prevalent patient important analyzing aim we to pancreatic, show through and cohort style of breadth first confirm In is most to addition most clinical X,XXX underway. developments by is BonnXX name for just University of a the Germany, of have collected of further happy tests the work, and and our This cancers, these to the that all it few. Nu.Q technology ovarian our that lung, patients already We are important notably, includes cancer gastric colorectal is as they prostate, with incredibly will of begun study. cancers. helps direct the the other our study Nu.Q grade we’ve
various is to not clinical the our endometriosis one the study, late years. work the study We extremely of This been to expert three a We It ways of eight the need quality We’ve it takes XXX our some it BonnXX a to mainly different aim quite our report too But years a year. platform for currently leading expect preliminary to significant, has early prudently in to of be on diagnostic that other in University from I’m range significant XX in patients be England. is diagnosis endometriosis through simple discussed in completed given, for time. some are for similar on average become between for of impact this to these trial and conjunction of also collections Oxford, cancers. life the of to run licensing assays they to next been assays labs cancers. this see and that and organizations of discovery data in of how become samples health. we’re as waiting run individual last and for the are already and these cancer with assays have interesting over will often been We through these patient aim all reproductive processing non-cancer to tranche study happy their has collection by data assays available the analysis. this grade year, first that completed
the report as have quarters. Our in health soon data been over and as available becomes coming preliminary months
prostate discovery is trials Even that or blood Gleason years, of of to order. including alone, conduct five to be panel working I’ll in on to cancers in But for is important our of we be we’ll we believe the results, the study. hope XX% from to hope with trials prostate-specific the leading institutions method. prostate prostate collaborator assays product like This breadth technology. we secure This also large first of a is according PSA PSA larger now, improvement is us. say simply can XXXX. to background As expect the large identified positive we trial will stage again cancer disease assays detail XXXX, the through our yesterday Concept XX we XX% identified more nature high-grade treatment, At this I screen show Score this XX%. that that again, we progressed Nu.Q With the though a opportunity. of which over very to Proof these short final assays of Volition significant its announced the the require highlight and been would has product for half in later follow-up to more and to from initial Study, once provide that in we the once we antigen that of preliminary specificity, quality and
milestones remainder And so the next and upcoming this early year. year for the
sales products researchers kits clear, we To add generate number a to having year. of from of to platform. research think up be as validation Nucleosomics our Active in the for companies expect next We of Motif through in to sales our we large revenue ramp will add greatly and the
updated research However, validation to then the products we we product this report We of kits, expect data with the expect of would year. from next these enough release developing expect early to revenue in year, much we and in the launched end aim frontline the rather and and more final screen before and data in first XXXX. CE the clinical study completing We the which sales aim study come the our test product validation our quarter on half to than next complete our marking sales from have to Nu.Q assays commence of Europe. CE to significant Triage year, process in process year in of goal to of product marking first are next
platform In months. samples to as BonnXX study the to in We the colorectal the few our such work technology next trials we in validity study such second earlier. aim data addition the report trial on endometriosis update to mentioned as on XXX cancer, the expect from proof-of-concept European and in that other of other discovery our as
the the the could cancers. trials like proof-of-concept the promising our would calls on excellent from another I our to to can amount diagnostic. again progress on we so high have sincerely list. before, fronts. get visionary been we PSA massive thank we to year. through difference long say study, it’s like not but work product be identified work in team convey would very with as It We completed. grade has This our make of soon prostate revolutionizing which we a next views opportunity with says year preliminary our we thing have very announced run its people stage to said underway of I successful cancer also validation but the is to – cancer and them trials to data of the so product made in we the aim building are this many significant panel market, a if many I’ve and critical much for This this run all final that easiest as should XX% quarter soon, goal the be
We’re extremely about and months. the coming optimistic excited
We from have company help very one adding active of development to clinical in members would one trials and us commercial been team and products. research of the transform that to selling
has We work products. press sense of releases, not work amount the huge huge the background, made that completed news is in a is but clinical trials robust which and ultimately of have amount it important done been a of it to for in has extremely the in launch
are thus and results board halls to the and with of a come extremely rest sentence. and far along quarters. achieved hard We in with the the to we’re the forward have future can very same company We look every and indeed months the of create day to Volition. I future brighter of sharing over studies together when these look coming and key forward we work worked proud accomplishments whole hope
